Publications

  • Manrique I, Nguewa P, Bleau AM, Nistal-Villan E, Lopez I, Villalba M, Gil-Bazo I, Calvo A. The inhibitor of differentiation isoform Id1b, generated by alternative splicing, maintains cell quiescence and confers self-renewal and cancer stem cell-like properties. Cancer Lett. 2015; 356(2 Pt B): 899-909. IF: 5.621. Lugar: 23/211 Oncology. Primer cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Arévalo E, Castañón E, López I, Salgado J, Collado V, Santisteban M, Rodríguez-Ruiz M, Martín P, Zubiri L, Patiño-García A, Rolfo C, Gil-Bazo I. Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed. J Transl Med. 2014; 12: 98. IF: 3.930. Lugar: 26/123 Medicine, Research & Experimental. Primer cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Castañón E, Martín P, Rolfo C, Fusco JP, Ceniceros L, Legaspi J, Santisteban M, Gil-Bazo I. Epidermal Growth Factor Receptor targeting in non-small cell lung cancer: revisiting different strategies against the same target. Curr Drug Targets. 2014; 15: 1273-83. IF: 3.021. Lugar: 77/254 Pharmacology and Pharmacy. Segundo cuartil.

  • Ponz-Sarvisé M, Castañón E, Panizo-Santos A, Redrado M, López I, Rosell D, Gil-Aldea I, Calvo A, Nguewa PA, Gil-Bazo I. Differential tumor expression of inhibitor of differentiation-1 in prostate cancer patients with extreme clinical phenotypes and prognostic implications. Clin Genitourin Cancer. 2014; 12: 87-93. IF: 2.322. Lugar: 27/76 Urology and Nephrology. Segundo cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Redrado M, Bodegas E, Villaro AC, Nguewa PA, Lopez I, Gil-Bazo I, Calvo A. Spatial-temporal protein expression of inhibitor of differentiation-1 (Id1) during fetal embryogenesis and in different mouse and human cancer types. Histol Histopathol. 2013; 28: 1029-40. IF: 2.096. Lugar: 34/75 Pathology. Segundo cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Castañón E, Bosch-Barrera J, López I, Collado V, Moreno M, López-Picazo JM, Arbea L, Lozano MD, Calvo A, Gil-Bazo I. Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy. J Transl Med. 2013; 11:13. IF: 3.930. Lugar: 26/123 Medicine, Research & Experimental. Primer cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Bosch-Barrera J, García-Franco C, Guillén-Grima F, Moreno-Jiménez M, López-Picazo JM, Gúrpide A, Pérez-Gracia JL, Aristu J, Torre W, García-Foncillas J, Gil-Bazo I. The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience. Clin Transl Oncol. 2012; 14: 835-41. IF: 2.077. Lugar: 147/2011 Oncology. Primer cuartil.

  • Ponz-Sarvisé M, Nguewa PA, Pajares MJ, Agorreta J, Lozano MD, Redrado Pío R, Behrens C, Wistuba I, García-Franco, CE, García-Foncillas J, Montuenga, LM, Calvo A, Gil-Bazo I. Inhibitor of differentiation-1 is a novel prognostic factor in NSCLC patients with adenocarcinoma histology and contributes to therapy resis- tance. Clinical Cancer Research 2011; 17: 4155-4166. IF: 8.722; Lugar: 12/211 Oncology. Primer decil.
    ABSTRACT CORTESÍA DE PUBMED

  • Gil-Bazo I, Castañón E, Fusco JP. EGFR mutation testing in nonsmall cell lung cancer patients by using cytology specimens: When the tissue is no longer the issue. Cancer Cytopathol. 2011; 119: 354. IF: 3.354. Lugar: 16/75 Pathology. Primer cuartil.



Dr. Ignacio Gil-Bazo.

More information:

Contact

Contact:
Marisol Ripa
Avda. Pío XII, 53
31008 Pamplona
Spain

(+34) 948 194 700 Ext. 1010
msripa@unav.es